Mealey's Antitrust/Unfair Competition - Pennsylvania Federal Judge Will Bar Evidence Of Litigation Uncertainty

PHILADELPHIA - The Federal Trade Commission on July 29 prevailed on a motion to preclude a pharmaceutical company from presenting evidence of "litigation uncertainty" surrounding its prescription drug patent at an upcoming reverse payments antitrust trial (Federal Trade Commission v. Cephalon Inc., No. 08-2141, E.D. Pa.).

Access this news story on®